Pemetrexed API Manufacturers & Suppliers

Pemetrexed (CAS 137281-23-3) is an antifolate chemotherapy agent indicated primarily for the treatment of malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC). It is approved for use in combination with cisplatin for patients with unresectable malignant pleural mesothelioma or those unsuitable for curative surgery. In NSCLC, pemetrexed is utilized as initial therapy in combination with pembrolizumab and platinum-based chemotherapy for metastatic disease lacking EGFR or ALK genomic alterations. It is also indicated as maintenance therapy following platinum-based treatment, as well as in second-line settings either as monotherapy or combined with cisplatin.

Pharmacologically, pemetrexed is a folate antimetabolite that disrupts essential folate-dependent enzymatic pathways required for DNA and RNA synthesis. It inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, thereby impairing de novo biosynthesis of thymidine and purine nucleotides. Cellular uptake occurs via the reduced folate carrier and folate binding protein transport systems. Inside cells, pemetrexed undergoes polyglutamation, enhancing retention and inhibitory activity predominantly within tumor tissues.

Key pharmacokinetic parameters include renal excretion as the main elimination route, with metabolism limited primarily to intracellular polyglutamation. Systemic exposure correlates with myelosuppression, specifically neutropenia, which necessitates folic acid and vitamin B12 supplementation to mitigate toxicity. Pemetrexed's narrow therapeutic index requires careful dosing and monitoring during treatment cycles, although cumulative hematologic toxicity appears minimal.

Safety considerations emphasize myelosuppression, renal toxicity, and potential for severe skin reactions. Supplementation protocols and patient renal function assessment are critical components of risk management. Pemetrexed is marketed under the brand name Alimta by Eli Lilly and Company and holds regulatory approvals in multiple jurisdictions.

From an API sourcing perspective, stringent quality controls are essential due to its narrow therapeutic index and complex polyglutamation-dependent mechanism of action. Consistency in purity, polymorphic form, and impurity profile must align with pharmacopeial standards and regulatory requirements to ensure clinical efficacy and safety. Reliable supply chains and validated manufacturing processes are critical to support pharmaceutical development and commercial production.